TABLE 4.
Generalized linear regression model on unit price of all procured cardiovascular medicines with difference-in-differences analyses.
Variables | β coefficient | Robust product clustered standard error | z | p>|z| | 95% confidence interval |
---|---|---|---|---|---|
Intervention effect (difference-in-differences) | −0.45 | 0.16 | −2.73 | 0.006 | −0.77 to -0.13 |
Generic competition (X1) | 0.17 | 0.20 | 0.87 | 0.385 | −0.22 to 0.57 |
(X1)2 | −0.02 | 0.02 | −0.63 | 0.526 | −0.06 to 0.03 |
Therapeutic competition (X2) | −0.38 | 0.13 | −3.03 | 0.002 | −0.63 to -0.13 |
(X2)2 | 0.01 | 0.01 | 1.35 | 0.176 | −0.00 to 0.02 |
Goodness-of-fit tests | |||||
Akaike Information Criterion (AIC) = 10.67 | |||||
Bayesian Information Criterion (BIC) = -79,081.63 |
Note: Bold values indicate regression coefficients with statistical significance (p < 0.05).